Premier Alternatives

Comanche Biopharma

Concord, MA · Founded 2020 · Privately Held (backing)

Operator of a biopharmaceutical company intended to develop an investigational siRNA medicine for preterm preeclampsia. Comanche Biopharma is based in Concord, MA and was founded in 2020. It was valued at $210 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $136 million across 2 recorded rounds; the latest was a $37.5 million early-stage round in Dec 2023.

PMV mark · valuation
$210.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$136.1M
Last round
Early Stage VC
Dec 2023

Comanche Biopharma key facts

as of Oct 2026
  • Operator of a biopharmaceutical company intended to develop an investigational siRNA medicine for preterm preeclampsia.
  • Comanche Biopharma is valued at approximately $210.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $136.1M across 2 recorded rounds; the latest was Early Stage VC ($37.5M) in Dec 2023.
  • Notable investors include GV, New Enterprise Associates, F-Prime Capital, Atlas Venture, Broadview Ventures — 8 tracked in total.
  • Comanche Biopharma has filed 2 Form Ds with the SEC since 2023, most recently Jan 2024 ($37.5M sold to 7 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$210.0M

Valued at $210.0M at its later-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Comanche Biopharma with a free account
  • ·Watch Comanche Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Comanche Biopharma funding rounds

2 rounds
Dec 2023Early Stage VC$37.5MSEC filing▮
Jun 2021Early Stage VC$36.1MSEC filing▮
Full funding history →

Comanche Biopharma valuation

Comanche Biopharma was valued at $210 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Comanche Biopharma raised?

Comanche Biopharma has raised $136 million in total; 2 of its rounds are on record. The largest on record was a $37.5 million early-stage round in Dec 2023.

Comanche Biopharma has filed 2 Form Ds with the SEC since 2023, most recently in Jan 2024 ($37.5 million sold to 7 investors).

Comanche Biopharma investors

8 investors are on record for Comanche Biopharma, including GV, New Enterprise Associates, F-Prime Capital and Atlas Venture. The early-stage round in Dec 2023 drew 7 investors.

About Comanche Biopharma

Operator of a biopharmaceutical company intended to develop an investigational siRNA medicine for preterm preeclampsia. The company provides access to evidence-based and affordable therapies for treating life-threatening complications of pregnancy, enabling women to avail themselves of cost-effective and sustainable preeclampsia treatment at its root cause.

Sector
Healthcare
HQ
Concord, MA, United States
Founded
2020
Employees
29
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.